NCT06211179View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

June 13, 2024

Study Completion Date

June 13, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

Treatment A: Mavacamten intact oral capsule

Specified dose on specified days

DRUG

Treatment B: Mavacamten open capsule in suspension

Specified dose on specified days

DRUG

Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube (NGT)

Specified dose on specified days

Trial Locations (1)

78217

Local Institution - 0001, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06211179 - A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants | Biotech Hunter | Biotech Hunter